What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence

by Rachel Hu, Daniel J. George, Tian Zhang
Published 2016-08-01

New approaches to first-line treatment of advanced renal cell carcinoma

by Daniel J. George, Chung-Han Lee, Daniel Heng
Published 2021-09-01

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

by Rhonda L. Bitting, Andrew J. Armstrong, Daniel J. George
Published 2011-01-01

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

by Rhonda L. Bitting, Andrew J. Armstrong, Daniel J. George
Published 2011-10-01

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma

by Zhiying Shao, Andrew Z. Wang, Daniel J. George, Tian Zhang
Published 2016-10-01

Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy

by Cierra Hong, Kristen A. Batich, Garland Almquist, Luis Villa, Daniel J. George, Tian Zhang
Published 2021-03-01

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

by Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, Tian Zhang
Published 2018-01-01

Novel therapies are changing treatment paradigms in metastatic prostate cancer

by Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang
Published 2020-10-01

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma

by Cristiane Decat Bergerot, Dena Battle, Paulo Gustavo Bergerot, Nazli Dizman, Eric Jonasch, Hans J. Hammers, Daniel J. George, Axel Bex, Borje Ljungberg, Sumanta Kumar Pal, Michael D. Staehler
Published 2019-01-01

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Published 2021-08-01

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Published 2021-09-01

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

by Matthew D. Tucker, Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Harrison, Yuan Wu, Patrick Healy, Stacey Lisi, Daniel J. George, Andrew J. Armstrong
Published 2019-08-01

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

by Ramy Sedhom, Santosh Gupta, Yuan Wu, Jason Zhu, Daniele Marin, Michael R Harrison, Landon C Brown, Matthew D Tucker, Eric B Schwartz, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Emmanuel S Antonarakis, Andrew J Armstrong
Published 2021-03-01

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer

by Tian Zhang, Anika Agarwal, R. Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, Chandra Rao, Monika Anand, Taofik Oyekunle, Patrick Healy, Megan A. McNamara, Kathryn Ware, Jason A. Somarelli, Daniel J. George, Andrew J. Armstrong
Published 2021-02-01

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

by Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia, Brian I. Rini
Published 2018-01-01

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

by Andrew J Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Kathryn Ware, Jason A Somarelli, Kris Wood, Thomas Ribar, Paraskevi Giannakakou, Jiaren Zhang, Drew Gerber, Monika Anand, Wen-Chi Foo, Susan Halabi, Simon G Gregory, Daniel J George
Published 2019-01-01

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

by Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins
Published 2019-12-01

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical out...

by Andrew L. Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita‐Saavedra, Landon C. Brown, Chester Kao, Emily N. Kinsey, Rajan T. Gupta, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T. Campbell
Published 2021-04-01

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

by Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Jonathan Andreas, Yirong Wang, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Rajan Gupta, Jason Zhu, Matthew Labriola, Shannon McCall, Daniel J. George, Pooja Ghatalia, Farshid Dayyani, Robert Edwards, Michelle S Park, Rajbir Singh, Robin Jacob, Saby George, Bo Xu, Matthew Zibelman, Razelle Kurzrock, Carl Morrison
Published 2020-01-01

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

by Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Published 2019-01-01